44 programming-"the"-"DAAD"-"IMPRS-ML"-"Virginia-Tech"-"IDAEA-CSIC"-"FEMTO-ST" "UCL" Fellowship positions
Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
. UCL is ranked 9th in the 2024 QS World University Rankings, 2nd in the UK for research power (Research Excellence Framework 2021) and our Neuroscience degree is ranked first in Europe (U.S. News and
-
organoid models of neurodevelopmental diseases to test advanced genetic therapies. It will be supervised by Professor Gabriele Lignani and is in collaboration with Dr Amy McTague at UCL Institute of Child
-
. UCL is ranked 9th in the 2024 QS World University Rankings, 2nd in the UK for research power (Research Excellence Framework 2021) and our Neuroscience degree is ranked first in Europe (U.S. News and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us UCL, based in Bloomsbury, is a welcoming, inclusive university situated at the heart of one of the world’s greatest cities. UCL is a top-ranked university in the UK for research in
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and